{"database": "lobbying", "table": "lobbying_activities", "rows": [[3047481, "62687c95-b67d-403a-a220-a00b1d3c4d89", "Q3", "PUBLIC CITIZEN", 32362, "PUBLIC CITIZEN", 2023, "third_quarter", "PHA", "S.1476 Pharmaceutical Research Transparency Act, S.954 Affordable Insulin Now Act, Medicare drug price negotiation implementation; Bayh-Dole royalty-free rights and contractual reasonable pricing conditions, NDAA government owned medical invention licensing, research and development transparency, and other transactions authority justification, pay for delay reform; product hopping reform; citizen petition abuse reform; FDA prescription drug transparency, S.2220 PREVAIL Act; S. 79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, We PAID Act", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 75000, 0, 0, "2023-10-11T14:31:22-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3047481"], "units": {}, "query_ms": 7.034235983155668, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}